With the FDA appearing to be undergoing major disruption under new leadership, BofA analyst Tim Anderson says one way to assess the risk from ...

COAST evaluated the efficacy and safety of intravitreally administered 2mg sozinibercept every four or eight weeks in ...

The US Food and Drug Administration (FDA) has approved an expanded label for fluocinolone acetonide intravitreal implant (ILUVIEN) that includes an indication for the treatment of chronic ...

had infringed on U.S. Patent 11,084,865, claimed to cover a vial containing Eylea. As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%.

Regeneron Pharmaceuticals Inc. failed to convince the Federal Circuit to block an Amgen Inc. biosimilar of Eylea while the competitors duke it out in a patent lawsuit. Amgen’s biosimilar formulation ...

Nova Scotia Loyal is a provincial program that labels products as being locally made. Nova Scotia-based Just Us Coffee had coffee beans with both the Nova Scotia Loyal branding and the maple leaf ...

The following guide provides key insights into how businesses can accurately label their products, ensuring both legal adherence and clear communication with customers. For food products, the CFIA ...

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest ...

Eylea has been one of Regeneron's top growth ... Regeneron and Sanofi are also seeking a label expansion for Dupixent in treating a rare skin disease called bullous pemphigoid.

At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This ...